Business Wire

MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline

Share

MapleStory,the iconic free-to-play global MMORPG from Nexon, has launched Neo: Light’s Wrath, Part Two of the massive summer content update that offers all new desert area, Hotel Arcus, offering new quests available to players level 270 and above. The Neo: Light’s Wrath update also adds the new Boss Seren and continues the Neo Castle, Tera Burning and Burning World Events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005292/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline (Photo: Business Wire)

Hidden secrets of the ancient gods will be unveiled in the Hotel Arcus desert area which has opened for players who have reached Level 270 and have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest. Following clues from the ancient gods will reveal the mysteries of the Hotel Arcus, offering a series of quests that will reward players with the Sacred Symbol: Arcus upon completion.After all Hotel Arcus quests are completed players can perform daily quests for Archelon in the Hotel Arcus Saloon that will reward Sacred Symbol: Arcus.

With the battle at Cernium at its end, Seren has emerged as god incarnate, wielding the power of the ancient gods. Players level 265 who have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest are able to test their strength against the powerful new boss Seren by entering a special portal in the Cernium Royal Palace Main Hall. By defeating Seren, players have the chance to earn Mitra’s Nodestone and Mitra’s Rage Emblem, part of the Pitched Boss Set. Mitra’s Nodestone unlocks the Solar Crest skill when used and Mitra’s Rage Emblem provides +40 primary stat/secondary stat for your class and +5 Attack/Magic Attack. Mitra’s Rage is tradable until equipped and can be equipped at level 200.

The Neo: Light’s Wrath Update continues the Neo Castle and Tera Burning and Burning World Events:

Neo Castle Event: Neo Castle isan area shrouded in mystery and was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events and mini-games including new ways to earn NEO currency with the following features and shops available:

  • Neo Stone Shop: Players can exchange Neo Stones for a variety of items that can be used to enhance equipment and boost character growth
  • Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
  • Neo Core Shop: Neo Cores can be collected by defeating bosses and can be used to purchase a variety of enhancement items
  • Neo Meso Shop: The Meso shop is stocked full of useful items and cosmetic items that can be purchased using Mesos

Burning World and Tera Burning Plus: Burning World and Tera Burning Plus events continue to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon if your Tera Burning Plus character reaches Lv. 220. Burning World Leap will begin August 25 and characters Lv. 150 and above will be able to leap to any non-Reboot world in their region.

To learn more about MapleStory, please visit http://maplestory.nexon.net

Assets - Neo: Light’s Wrath Video - Artwork

Social Media:TikTok / Twitter / Instagram / Twitch / Facebook / YouTube / Website

About MapleStory https://maplestory.nexon.net

MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.

About Nexon America Inc.https://www.nexon.com/

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brian Klotz
Nexon America
pr@nexon.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye